Peter Thompson Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 29,063 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the sale, the director directly owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. This represents a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Sionna Therapeutics Price Performance

Shares of NASDAQ:SION opened at $35.25 on Friday. The company has a market capitalization of $1.57 billion and a P/E ratio of -7.24. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The firm’s 50 day simple moving average is $41.23 and its two-hundred day simple moving average is $32.82.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Sionna Therapeutics News Summary

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Analyst consensus and price targets provide upside context — brokers’ average target (~$45.43) and several buy/strong‑buy reports give the stock valuation support versus current levels, suggesting analysts expect further recovery over time. Read More.
• Neutral Sentiment: Upcoming investor event could be a catalyst — management will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb. 11; the presentation may supply pipeline updates or Q&A that could move the stock depending on tone and new details. Read More.
• Negative Sentiment: Insider and institutional selling produced near‑term downward pressure — Director Peter A. Thompson and Orbimed Advisors LLC disclosed sales of 29,063 shares (plus an additional 1,890-share trim) at ~ $44.57–$44.58. Although the sales represent small percentages of large holdings, they add liquidity and can prompt stop‑loss or momentum selling around those price levels. Read More. Read More.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SION. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a research note on Monday, December 1st. Lifesci Capital started coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Institutional Trading of Sionna Therapeutics

Several hedge funds have recently modified their holdings of the company. Braidwell LP purchased a new position in shares of Sionna Therapeutics in the second quarter valued at $18,770,000. Vanguard Group Inc. raised its stake in Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares in the last quarter. Viking Global Investors LP lifted its position in Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the last quarter. Aberdeen Group plc grew its stake in shares of Sionna Therapeutics by 27.4% in the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock worth $16,492,000 after buying an additional 204,583 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Sionna Therapeutics by 1,425.5% in the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock worth $6,296,000 after buying an additional 200,051 shares during the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.